Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKRO Akero Therapeutics	$48.31 +0.6%	$52.13	$21.34 ▼ $58.40	$3.84B	-0.28	1.07 million shs	838,999 shs
AXSM Axsome Therapeutics	$109.39 +4.0%	$105.71	$75.56 ▼ $139.13	$5.25B	0.51	630,955 shs	589,197 shs
PCVX Vaxcyte	$31.55 +5.2%	$34.18	$27.66 ▼ $121.06	$3.89B	1.21	1.24 million shs	2.64 million shs
TVTX Travere Therapeutics	$18.05 +3.7%	$15.59	$8.46 ▼ $25.29	$1.55B	0.74	1.42 million shs	1.65 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKRO Akero Therapeutics	+0.58%	-8.49%	-8.38%	+20.90%	+95.03%
AXSM Axsome Therapeutics	+3.95%	+5.94%	-2.62%	+2.02%	+28.92%
PCVX Vaxcyte	+5.17%	-4.39%	-13.28%	+2.10%	-59.14%
TVTX Travere Therapeutics	+3.68%	+4.70%	+6.74%	-14.66%	+104.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKRO Akero Therapeutics	4.0961 of 5 stars	3.5	3.0	4.7	3.3	0.8	0.0
AXSM Axsome Therapeutics	4.8293 of 5 stars	4.5	3.0	4.5	2.4	4.2	0.6
PCVX Vaxcyte	2.0119 of 5 stars	3.5	2.0	0.0	2.3	1.7	0.0
TVTX Travere Therapeutics	2.0508 of 5 stars	3.4	1.0	0.0	3.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKRO Akero Therapeutics	3.00	Buy	$81.57	68.85% Upside
AXSM Axsome Therapeutics	3.07	Buy	$178.00	62.72% Upside
PCVX Vaxcyte	3.09	Buy	$136.50	332.65% Upside
TVTX Travere Therapeutics	2.87	Moderate Buy	$32.21	78.47% Upside

Current Analyst Ratings Breakdown

Latest TVTX, AXSM, AKRO, and PCVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/7/2025	TVTX Travere Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	PCVX Vaxcyte	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/7/2025	TVTX Travere Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$30.00 ➝ $31.00
8/7/2025	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$30.00 ➝ $32.00
8/5/2025	AXSM Axsome Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$173.00 ➝ $176.00
8/5/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$184.00 ➝ $189.00
8/4/2025	AKRO Akero Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
8/4/2025	AKRO Akero Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$76.00
8/4/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$150.00
7/3/2025	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$190.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$12.82 per share	N/A
AXSM Axsome Therapeutics	$385.69M	14.15	N/A	N/A	$1.46 per share	74.92
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$23.66 per share	N/A
TVTX Travere Therapeutics	$333.87M	4.82	N/A	N/A	$0.37 per share	48.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKRO Akero Therapeutics	-$252.06M	-$2.00	N/A	N/A	N/A	N/A	-15.84%	-14.59%	N/A
AXSM Axsome Therapeutics	-$287.22M	-$5.07	N/A	38.79	N/A	-49.88%	-283.22%	-33.06%	N/A
PCVX Vaxcyte	-$463.93M	-$4.11	N/A	N/A	N/A	N/A	-16.85%	-15.92%	N/A
TVTX Travere Therapeutics	-$321.55M	-$2.04	N/A	N/A	N/A	-50.64%	-717.68%	-30.69%	10/30/2025 (Estimated)

Latest TVTX, AXSM, AKRO, and PCVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	AKRO Akero Therapeutics	-$0.97	-$0.86	+$0.11	-$0.86	N/A	N/A
8/6/2025	Q2 2025	PCVX Vaxcyte	-$1.12	-$1.22	-$0.10	-$1.22	N/A	N/A
8/6/2025	Q2 2025	TVTX Travere Therapeutics	-$0.28	-$0.14	+$0.14	-$0.14	$100.18 million	$94.84 million
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.00	-$0.92	+$0.08	-$0.97	$140.02 million	$150.04 million
5/14/2025	Q1 2025	PCVX Vaxcyte	-$1.02	-$1.04	-$0.02	-$1.04	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKRO Akero Therapeutics	0.02	12.66	16.80
AXSM Axsome Therapeutics	1.66	1.57	1.51
PCVX Vaxcyte	N/A	11.11	11.11
TVTX Travere Therapeutics	9.50	2.00	1.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKRO Akero Therapeutics	N/A
AXSM Axsome Therapeutics	81.49%
PCVX Vaxcyte	96.78%
TVTX Travere Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AKRO Akero Therapeutics	7.07%
AXSM Axsome Therapeutics	22.30%
PCVX Vaxcyte	3.10%
TVTX Travere Therapeutics	4.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKRO Akero Therapeutics	30	79.99 million	74.33 million	Optionable
AXSM Axsome Therapeutics	380	49.90 million	38.77 million	Optionable
PCVX Vaxcyte	160	129.82 million	125.80 million	Optionable
TVTX Travere Therapeutics	460	89.14 million	85.40 million	Optionable

TVTX, AXSM, AKRO, and PCVX Headlines

Recent News About These Companies

Connor Clark & Lunn Investment Management Ltd. Boosts Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

August 13 at 4:26 AM | marketbeat.com

TVTX FY2025 EPS Forecast Boosted by Cantor Fitzgerald

August 12 at 3:02 AM | americanbankingnews.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Rating of "Moderate Buy" by Analysts

August 12 at 2:16 AM | marketbeat.com

Cantor Fitzgerald Issues Positive Outlook for TVTX Earnings

August 11 at 2:31 AM | marketbeat.com

Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $31.00

August 10, 2025 | americanbankingnews.com

Wedbush Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock

August 10, 2025 | americanbankingnews.com

Travere Therapeutics price target raised to $32 from $30 at Wedbush

August 8, 2025 | finance.yahoo.com

Travere Therapeutics (NASDAQ:TVTX) Given New $31.00 Price Target at Scotiabank

August 8, 2025 | marketbeat.com

Wedbush Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $32.00

August 8, 2025 | marketbeat.com

Travere Therapeutics shares rise as Q2 results top expectations

August 7, 2025 | investing.com

Travere Therapeutics Reports Strong Q2 2025 Growth

August 7, 2025 | msn.com

Travere Therapeutics, Inc. (TVTX) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

Travere Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 6, 2025 | seekingalpha.com

Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings

August 6, 2025 | zacks.com

Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates

August 6, 2025 | zacks.com

Earnings Preview: Travere Therapeutics

August 5, 2025 | benzinga.com

XTX Topco Ltd Has $935,000 Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

August 4, 2025 | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Short Interest Update

August 2, 2025 | marketbeat.com

Travere Therapeutics (TVTX) Expected to Announce Earnings on Thursday

July 31, 2025 | marketbeat.com

Travere Therapeutics to Report Second Quarter 2025 Financial Results

July 30, 2025 | businesswire.com

Essex Investment Management Co. LLC Makes New Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX)

July 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVTX, AXSM, AKRO, and PCVX Company Descriptions

Akero Therapeutics NASDAQ:AKRO

$48.31 +0.28 (+0.58%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$48.15 -0.16 (-0.33%)

As of 08/13/2025 06:45 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Axsome Therapeutics NASDAQ:AXSM

$109.39 +4.16 (+3.95%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$107.47 -1.92 (-1.76%)

As of 08/13/2025 07:53 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Vaxcyte NASDAQ:PCVX

$31.55 +1.55 (+5.17%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$31.11 -0.44 (-1.39%)

As of 08/13/2025 06:54 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Travere Therapeutics NASDAQ:TVTX

$18.05 +0.64 (+3.68%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$17.89 -0.16 (-0.89%)

As of 08/13/2025 07:07 PM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time